The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis
Open accessAbstract
Although anecdotal reports suggest that cannabis may be used to alleviate symptoms of depression, the psychotropic effects and abuse liability of this drug prevent its therapeutic application. The active constituent of cannabis, Δ 9 -tetrahydrocannabinol, acts by binding to brain CB 1 cannabinoid receptors, but an alternative approach might be to develop agents that amplify the actions of endogenous cannabinoids by blocking their deactivation. Here, we show that URB597, a selective inhibitor of the enzyme fatty-acid amide hydrolase, which catalyzes the intracellular hydrolysis of the endocannabinoid anandamide, exerts potent antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test. Moreover, URB597 increases firing activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in the nucleus locus ceruleus. These actions are prevented by the CB 1 antagonist rimonabant, are accompanied by increased brain anandamide levels, and are maintained upon repeated URB597 administration. Unlike direct CB 1 agonists, URB597 does not exert rewarding effects in the conditioned place preference test or produce generalization to the discriminative effects of Δ 9 -tetrahydrocannabinol in rats. The findings support a role for anandamide in mood regulation and point to fatty-acid amide hydrolase as a previously uncharacterized target for antidepressant drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
The Neuroendocrinology of Stress: A Never Ending Story
Lightman, S. L. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01711.x · Cited by 3,566
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Self-citationRole of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Self-citationModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Self-citationControl of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
Self-citationAn endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
Self-citation
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…al., 2006), and the amplification of the actions of endocannabinoids by the FAAH inhibitor URB597 was found to produce antidepressant-like effects in the mouse tailsuspension and rat forced-swim tests, without eliciting reward-related effects indicative of addictive potential (Gobbi et al., 2005).”
BackgroundNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Tzschentke, T. M. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00070.x · Cited by 1,336
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
“…of the developing brain (Buckley et al. 1998), activation of CB1 is required for the axonal growth response (Williams et al. 2003), the endocannabinoid system drives neural progenitor cell proliferation (Aguado et al. 2006), and cannabinoids actually promote neurogenesis (Berghuis et al. 2007).”
BackgroundTargeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
“This name reflects a good foresight, because anandamide plasma levels are significantly reduced in patients with major depression (Hill et al., 2009), and blockade of anandamide hydrolysis exerts robust anti-depressant-like effects (Gobbi et al., 2005).”
BackgroundEndocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597)
Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T. R., Dasse, O., Monaghan, E. P., Parrott, J. A., & Putman, D. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00021.x · Cited by 441
Self-citationThe serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors
Marrs, W. R., Blankman, J. L., Horne, E. A., Thomazeau, A., Lin, Y. H., Coy, J., Bodor, A. L., Muccioli, G. G., Hu, S. S.-J., Woodruff, G., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2601 · Cited by 441
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.013 · Cited by 439
Goodman, A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.030 · Cited by 413
Patel, S., & Hillard, C. J. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101287 · Cited by 392
Long, J. Z., Nomura, D. K., Vann, R. E., Walentiny, D. M., Booker, L., Jin, X., Burston, J. J., Sim-Selley, L. J., Lichtman, A. H., Wiley, J. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909411106 · Cited by 391
Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
“Genetic or pharmacological inactivation of FAAH1 produces analgesic, anti-inflammatory, antidepressant and sleep-enhancing phenotypes in rodents, particularly in models of inflammatory pain [2,4,6,12,16,17,19,21,24,25,27,30,33,37,39,40,47].”
BackgroundBortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347
Self-citationRubino, T., Vigano', D., Realini, N., Guidali, C., Braida, D., Capurro, V., Castiglioni, C., Cherubino, F., Romualdi, P., Candeletti, S., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301664 · Cited by 345
Chemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327
Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-07.2007 · Cited by 325
Self-citationMansur, R. B., Brietzke, E., & McIntyre, R. S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.017 · Cited by 322
Campolongo, P., Roozendaal, B., Trezza, V., Hauer, D., Schelling, G., McGaugh, J. L., & Cuomo, V. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900835106 · Cited by 294
Self-citationSerum Endocannabinoid Content is Altered in Females with Depressive Disorders: A Preliminary Report
Hill, M., Miller, G., Ho, W.-S., Gorzalka, B., & Hillard, C. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-993211 · Cited by 292
Moreira, F. A., Kaiser, N., Monory, K., & Lutz, B. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.005 · Cited by 281
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272
Endocannabinoid signaling in microglial cells
Stella, N. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.037 · Cited by 272
El-Alfy, A. T., Ivey, K., Robinson, K., Ahmed, S., Radwan, M., Slade, D., Khan, I., ElSohly, M., & Ross, S. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.004 · Cited by 268
Supply and demand for endocannabinoids
Alger, B. E., & Kim, J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.03.003 · Cited by 268
Hill, M. N., Carrier, E. J., McLaughlin, R. J., Morrish, A. C., Meier, S. E., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05567.x · Cited by 246
“…of the ECS has been shown to produce an antidepressant response alone and to enhance the effects of conventional antidepressants in several rodent models of antidepressant efficacy (Bortolato et al. 2007; Filip et al. 2006; Gobbi et al. 2005; Hill and Gorzalka 2005b; Hill et al. 2007b).”
BackgroundInfluentialCannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213
“…catalyzing the intracellular hydrolysis of the endocannabinoid AEA, was found to produce antidepressant-like effects in the mouse tail-suspension test and the rat forced-swim test without eliciting rewardrelated effects indicative of addictive potential (Gobbi et al. 2005; Bortolato et al. 2007).”
BackgroundMethodEffects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
Gorzalka, B. B., Hill, M. N., & Hillard, C. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.004 · Cited by 211
“Specifically, these pharmacological agents have been shown to facilitate adaptive stress coping behaviors in the forced swim test (Gobbi et al., 2005; Hill and Gorzalka, 2005a; Hill et al., 2007), tail suspension test (Gobbi et al., 2005) and chronic mild stress paradigm (Bortolato et al., 2007).”
BackgroundInfluentialEvaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184
“Conversely, employing similar lighting conditions as those used by Gobbi et al. (2005) and increasing the sample size of each group revealed significant effects of both URB597 and FAAH deletion in the tail suspension assay.”
BackgroundMethodInfluentialGoods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Self-citationRusso, R., LoVerme, J., La Rana, G., Compton, T. R., Parrott, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119941 · Cited by 182
Self-citationEndocannabinoid signalling: has it got rhythm?
Vaughn, L. K., Denning, G., Stuhr, K. L., de Wit, H., Hill, M. N., & Hillard, C. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00790.x · Cited by 176
Bambico, F. R., Nguyen, N.-T., Katz, N., & Gobbi, G. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.020 · Cited by 161
Self-citationPatel, S., & Hillard, C. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06266.x · Cited by 162
Bidirectional cannabinoid modulation of social behavior in adolescent rats
Trezza, V., & Vanderschuren, L. J. M. J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1025-3 · Cited by 159
Self-citationEvaluation of NHS Carbamates as a Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors
Niphakis, M. J., Cognetta, A. B., Chang, J. W., Buczynski, M. W., Parsons, L. H., Byrne, F., Burston, J. J., Chapman, V., & Cravatt, B. F. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400116z · Cited by 157
Shonesy, B. C., Bluett, R. J., Ramikie, T. S., Báldi, R., Hermanson, D. J., Kingsley, P. J., Marnett, L. J., Winder, D. G., Colbran, R. J., & Patel, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.001 · Cited by 155
Sartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.033 · Cited by 156
Melancia, F., Schiavi, S., Servadio, M., Cartocci, V., Campolongo, P., Palmery, M., Pallottini, V., & Trezza, V. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14435 · Cited by 145
Self-citationMore surprises lying ahead. The endocannabinoids keep us guessing
Piomelli, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.026 · Cited by 128
Self-citationPassie, T., Emrich, H. M., Karst, M., Brandt, S. D., & Halpern, J. H. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1377 · Cited by 117
Davis, M. L., Powers, M. B., Handelsman, P., Medina, J. L., Zvolensky, M., & Smits, J. A. J. (2015) · Evaluation & the Health Professions · doi:10.1177/0163278714529970 · Cited by 114
“Importantly, it appears that these withdrawal symptoms are strongly related to the downregulation of brain endocannabinoids resulting from frequent cannabis use (Bortolato et al., 2006, 2007; Clapper et al., 2009; Gobbi et al., 2005).”
BackgroundAnhedonia in depression symptomatology: appetite dysregulation and defective brain reward processing
Coccurello, R. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112041 · Cited by 106
Regulation of Inflammatory Pain by Inhibition of Fatty Acid Amide Hydrolase
Naidu, P. S., Kinsey, S. G., Guo, T. L., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164806 · Cited by 108
“Blockade of endocannabinoid metabolism could, however, have the added advantage in inflammatory states, such as rheumatoid arthritis, by producing dual anti-inflammatory and antihyperalgesic effects, albeit without the potential for abuse or dependence (Gobbi et al., 2005), as in the case of direct cannabinoid recepto…”
BackgroundDe Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.022 · Cited by 110
Self-citationZhang, D., Saraf, A., Kolasa, T., Bhatia, P., Zheng, G. Z., Patel, M., Lannoye, G. S., Richardson, P., Stewart, A., Rogers, J. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.009 · Cited by 99
Sasso, O., Bertorelli, R., Bandiera, T., Scarpelli, R., Colombano, G., Armirotti, A., Moreno-Sanz, G., Reggiani, A., & Piomelli, D. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.02.012 · Cited by 96
“Preclinical studies have shown that URB597 readily enters the CNS and exerts a combination of anxiolytic, antidepressant and analgesic effects [9, 13, 14].”
BackgroundSelf-citationEndocannabinoid signaling and the hypothalamic-Pituitary-Adrenal axis
Hillard, C. J., Beatka, M., & Sarvaideo, J. (2016) · Comprehensive physiology · doi:10.1002/cphy.c160005 · Cited by 93
“Genetic deletion studies in mice (22) and studies using pharmacologic inhibitors of FAAH (40) and MAGL (111) consistently demonstrate that the activities of these hydrolytic enzymes play a very important role in the regulation of CB1R activation.”
Endocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92
Geddes, S. D., Assadzada, S., Lemelin, D., Sokolovski, A., Bergeron, R., Haj-Dahmane, S., & Béïque, J.-C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522754113 · Cited by 90
Zhang, Z., Wang, W., Zhong, P., Liu, S. J., Long, J. Z., Zhao, L., Gao, H., Cravatt, B. F., & Liu, Q. (2015) · Hippocampus · doi:10.1002/hipo.22344 · Cited by 89
Aguilar-Valles, A., Haji, N., De Gregorio, D., Matta-Camacho, E., Eslamizade, M. J., Popic, J., Sharma, V., Cao, R., Rummel, C., Tanti, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04883-5 · Cited by 82
Self-citationChapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs
Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., & Cuomo, V. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)85005-8 · Cited by 83
Self-citationRossi, S., De Chiara, V., Musella, A., Sacchetti, L., Cantarella, C., Castelli, M., Cavasinni, F., Motta, C., Studer, V., Bernardi, G., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064196 · Cited by 82
“It also reduces stressinduced depressive symptoms (Gobbi et al., 2005; Rademacher and Hillard, 2007), inappropriate retention of aversive memories (Ganon-Elazar and Akirav, 2009), and cognitive deficits (Hill et al.”
BackgroundInfluentialHill, M. N., Ho, W.-S. V., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0131-7 · Cited by 75
Cassano, T., Gaetani, S., Macheda, T., Laconca, L., Romano, A., Morgese, M. G., Cimmino, C. S., Chiarotti, F., Bambico, F. R., Gobbi, G., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2051-0 · Cited by 72
Self-citationHaj-Dahmane, S., & Shen, R.-Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153858 · Cited by 69
Manduca, A., Servadio, M., Campolongo, P., Palmery, M., Trabace, L., Vanderschuren, L. J. M. J., Cuomo, V., & Trezza, V. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.05.009 · Cited by 66
Self-citationEndocannabinoid signaling in social functioning: an RDoC perspective
Karhson, D. S., Hardan, A. Y., & Parker, K. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.169 · Cited by 62
PPARα modulation of mesolimbic dopamine transmission rescues depression-related behaviors
Scheggi, S., Melis, M., De Felice, M., Aroni, S., Muntoni, A. L., Pelliccia, T., Gambarana, C., De Montis, M. G., & Pistis, M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.024 · Cited by 56
Manwell, L. A., Satvat, E., Lang, S. T., Allen, C. P., Leri, F., & Parker, L. A. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.08.002 · Cited by 48
De Chiara, V., Motta, C., Rossi, S., Studer, V., Barbieri, F., Lauro, D., Bernardi, G., & Centonze, D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.06.069 · Cited by 37
Carnevali, L., Vacondio, F., Rossi, S., Callegari, S., Macchi, E., Spadoni, G., Bedini, A., Rivara, S., Mor, M., & Sgoifo, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.015 · Cited by 34
Hauer, D., Weis, F., Campolongo, P., Schopp, M., Beiras-Fernandez, A., Strewe, C., Giehl, M., Toth, R., Kilger, E., & Schelling, G. (2012) · Reviews in the Neurosciences · doi:10.1515/revneuro-2012-0058 · Cited by 33
Wills, K. L., Vemuri, K., Kalmar, A., Lee, A., Limebeer, C. L., Makriyannis, A., & Parker, L. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3575-5 · Cited by 29
The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics
Ahmed, M., Boileau, I., Le Foll, B., Carvalho, A. F., & Kloiber, S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1926 · Cited by 11
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7
Self-citation
Metadata
- Authors
- Gobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., Tontini, A., Tarzia, G., Mor, M., Trezza, V., Goldberg, S. R., Cuomo, V., & Piomelli, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-12-13
- Volume
- 102
- Issue
- 51
- Pages
- 18620-18625
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2103659596
- Cited by
- 673
- References
- 42
- FWCI
- 27.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.